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PURPOSE.We investigate if the BMP4/Smad1 intracellular signaling pathway is neuroprotective
and axogenic in adult rodent retinal ganglion cells (RGC) in vivo and in vitro.
METHODS. Adult retinal cultures were prepared from intact and after optic nerve crush
(ONC) injured rats that have been stimulated to survive and regenerate using an intravitreal
peripheral nerve (PN) graft. Laser capture microdissection (LCM) then was used to isolate
RGC with and without neurites. Quantitative RT-PCR determined changes in BMP4/Smad1
signaling pathway mRNA. Immunohistochemistry confirmed localization of BMP4 and
activation of Smad1 in ONCþPN-stimulated RGC in vivo. BMP4 peptide was used to
stimulate RGC survival and neurite/axon regeneration in vitro and in vivo. Finally, the
rapamycin sensitivity of the effects was determined in BMP4-stimulated RGC in vitro and in
vivo.
RESULTS. In retinal cultures prepared from intact and ONCþPN-stimulated rats, RGC with
neurites had upregulated regeneration-related and BMP4/Smad1 signaling pathway mRNA
levels, while low levels of these mRNAs were present in RGC isolated without neurites. An
optimal dose of 200 ng/mL BMP4 peptide in vitro promoted approximately 30% RGC survival
and disinhibited RGC neurite outgrowth, despite the presence of inhibitory CNS myelin
extracts. BMP4 also promoted approximately 30% RGC survival in vivo and stimulated
significant RGC axon regeneration at 100, 200, and 400 lm beyond the lesion site. Finally, the
response of RGC to BMP4 treatment in vitro and in vivo was rapamycin-insensitive.
CONCLUSIONS. Activation of the BMP4/Smad1 pathway promotes survival and axon
regeneration independent of mTOR and, therefore, may be of therapeutic interest.
Keywords: optic nerve crush, retinal ganglion cells, neuroprotection, laser capture
microdissection, BMP4, Smad1
Axon regeneration in the adult mammalian central nervoussystem (CNS) is limited after injury by a multiplicity of
factors, including a low intrinsic capacity of adult neurons to
regrow their axons and the presence of myelin- and scar-
derived axon inhibitory factors.1–5 However, intrinsic factors,
such as cyclic adenosine monophosphate (cAMP), mammalian
target of rapamycin (mTOR), and the repressors phosphatase
and tensin homolog (PTEN) and suppressor of cytokine
signaling 3 (SOCS3) promote CNS axon regeneration.6–9 The
observation that mTOR activity is developmentally downregu-
lated and new protein synthesis is suppressed after mTOR
inactivation probably explains why some axons do not
normally regenerate in the mature CNS.10,11
Other pathways known to have a role in RGC axon
regeneration include those activated by inflammatory stimula-
tion, such as oncomodulin12–14 and activation of the JAK/STAT3
pathway,15–17 transcritptional repressors, such as Kruppel-like-
factors (KLFs),18,19 Sox11,20 and c-Myc.21 However, the
regenerative effects remain limited, since for example, activa-
tion of mTOR or overexpression of osteopontin and insulin-like
growth factor 1 (IGF1) promotes selective regeneration of a
small proportion of a-RGC that comprise only 6% of RGC in an
intact retina.22 Therefore, other pathways must be identified to
promote regeneration of a greater population of RGC.
One possible novel candidate therapeutic target is bone
morphogenetic protein 4 (BMP4) and the downstream small
mothers against decapentaplegic 1 (Smad1) signaling pathway
that it activates. BMPs are essential in retinal development,
upregulated after retinal injury, and activated downstream
Smad1 signaling is neuroprotective for RGC.23–28 In addition,
exogenous addition of BMP4 promotes the survival of RGC after
NMDA-mediated damage,28 but RGC axon regeneration has not
been studied after BMP4/Smad1 activation. However, in a
conditioning lesion, where the peripheral branch of the dorsal
root ganglia (DRG) is axotomized, Smad1 signaling is induced
and is required for the enhanced axon growth potential, while a
central axotomy failed to activate Smad1.29 Intrathecal injection
of AAV-BMP4 to overexpress BMP4 in DRG neurons activated
Smad1 signaling and promoted sensory axon regeneration after
spinal cord injury in the mouse.30 Therefore, we reasoned that
BMP4/Smad1 signaling might also be activated in RGC
regenerating their axons and that intravitreal delivery of a
BMP4 peptide may promote RGC survival and axon regener-
ation.
We isolated RGC somata by laser capture microdissection
(LCM) from two RGC populations: those that did and did not
grow neurites. LCM was undertaken in the same culture dish in
intact and optic nerve crush plus intravitreal peripheral nerve
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(ONCþPN)-treated retinal cultures and activity of the BMP4/
Smad1 pathway investigated in RGC that grew neurites versus
those that did not. In both RGC populations, signaling
components of the BMP4/Smad1 pathway were highly active
in RGC with neurites. BMP4 peptides disinhibited RGC neurite
outgrowth in the presence of inhibitory CNS myelin extracts
(CME) in vitro31 and promoted significant RGC survival and
axon regeneration in vivo. Taken together, these results
showed that BMP4/Smad1 could be a constituent of a
neurotrophic factor cocktail required to promote RGC axon
regeneration, thereby achieving greater RGC axon reconnec-
tion with denervated targets after visual pathway trauma and
the reinstatement of visual function.
METHODS
In Vitro Experiments
Experimental Design. For the LCM studies, dissociated
retinal cultures from n ¼ 12 intact (uninjured) adult female
Sprague-Dawley rats (170–220 g; Charles River, Margate,
United Kingdom) were grown in triplicates (3 independent
repeats, n ¼ 9 wells/treatment) or adult Fischer rats (Charles
River) prestimulated to grow by intravitreal sciatic nerve graft
implantation (ONCþPN)32 for 21 days before harvesting retinae
and dissociating retinal cells (n ¼ 3 rats/experiment, three
independent repeats, n ¼ 9 wells/treatment) as described
above (Figs. 1A, 1B).
FIGURE 1. Experimental design for in vitro and in vivo experiments. (A) Timelines for the in vitro studies including retinal cultures prepared from
na¨ıve rats and 21 days after ONCþPN implantation. (B) Timeline of in vivo ONCþPN implantation study, treatment groups, and measured endpoints.
(C) Timeline of in vivo BMP4 study, treatment groups, and measured endpoints.
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Mixed Adult Rat Retinal Cultures. Retinal cultures were
prepared from either intact 6- to 8-week-old Sprague-Dawley
rats (180–220 g; Charles River) or 6- to 8-week-old Fischer rats
(Charles River; to avoid SN graft rejection) at 21 days after
ONCþPN implantation.32 Retinal cells were dissociated using a
Papain dissociation kit and 125 3 103 cells cultured in 8-well
chamber slides and grown in Neurobasal-A medium supple-
mented with B27 supplement and L-glutamine (all from
Invitrogen, Paisley, United Kingdom), with appropriate treat-
ments for 3 days at 378C and 5% CO2.
16
For LCM, dissociated retinal cells were grown on polyeth-
ylene terephthalate (PET) membranes (Leica Microsystems,
Milton Keynes, United Kingdom) coated with 10 lg/mL poly-L-
lysine for 3 days in a humidified chamber. To stimulate neurite
outgrowth, preoptimized NTF consisting of neurotrophin
(NT)-3 (50 ng/mL), fibroblast growth factor 2 (FGF2; 10 ng/
mL) and brain-derived neurotrophic factor (BDNF; 50 ng/mL;
referred to as ‘‘combined NTF’’ from herein; all purchased from
Peprotech, London, United Kingdom) were used.33
To assess BMP4-mediated disinhibition of RGC neurite
outgrowth, retinal cells were prepared from intact 6- to 8-
week-old Sprague-Dawley rats (Charles River) as above and
treated with increasing concentrations of BMP4 peptide
(Peprotech) from 0–300 ng/mL in the presence of preopti-
mized CNS myelin extracts (CME).31,34 Retinal cultures were
incubated for 3 days with the appropriate treatments before
fixing in 4% paraformaldehyde in PBS (TAAB, Peterborough,
United Kingdom) for 10 minutes at room temperature (RT) as
described previously35 and subjected to bIII-tubulin immuno-
cytochemistry and RGC neurite outgrowth analysis, as
described above (Fig. 1A).
To test if BMP4-mediated RGC neurite outgrowth is
sensitive to Rapamycin, retinal cells also were treated with
10 nM rapamycin (LC Laboratories, Woburn, Boston, USA) for 3
days.36
siRNA Experiments. To confirm a role for BMP4, we
knocked down BMP receptors and downstream Smad1 in
BMP4 stimulated and assessed RGC survival and neurite
outgrowth. There are three type I receptors of the TGFb-
superfamily that binds BMP4, namely type 1A BMP receptor
(BMPR-1A), type 1B BMP receptor (BMPR-1B), and type 1A
activin receptor (ACVR1).37 We purchased a set of four siRNAs
of each, pooled together to guarantee knockdown and targeted
against rat BMPR1a (SMARTpool siRNA, M-088678-01-005;
siBMPR1A), BMPR1b (SMARTpool siRNA, M089942-01-0005;
siBMPR1b), ACVR1 (SMARTpool siRNA, M-099048-01-0005;
siACVR1), and Smad1 (SMARTpool, M094977-01-0005; siS-
mad1; all from Dharmacon, Lafayette, CO, USA). A negative
control, comprised of four nontargeting siRNAs (siControl) also
was included in each run as well as transfection reagent alone
controls. In a preliminary experiment, we determined 5 nM of
each siRNA to optimally knock down the relevant mRNA in
retinal cultures. Retinal cultures then were cultured in the
presence of optimal concentrations of BMP4, allowed to
incubate for 3 days before immunocytochemistry for bIII-
tubulin to determine RGC survival and neurite outgrowth, as
described below.
Mixed retinal cells were transfected with siRNA using
Lipofectamine 2000 reagent (Invitrogen) as described previ-
ously.38 Breifly, siRNA and transfection reagent were each
diluted in supplemented neomycin anaerobic blood agar (NBA)
culture medium (without antibiotics) and incubated for 5
minutes at room temperature. The two solutions were
combined, gently mixed, and incubated for a further 25
minutes at room temperature to form siRNA-reagent complex-
es. Complexes were diluted to the desired concentrations in
NBA, added to the cells, and transfected for 5 hours before
addition of supplemented NBA to a final volume of 500 lL per
well, and incubated at 378C and 5% CO2 for a further 3 days.
Culture medium alone, lipofectamine reagent without siRNA,
and control siRNA were used as controls. A dose-response
assay was done initially, for all siRNAs and tested at 2.5, 5, 10,
20, and 50 nM concentrations, confirming that a concentration
of 5 nM caused optimal mRNA knockdown in retinal cultures.
Immunocytochemistry of Retinal Cultures. Retinal
cells were permeabilized and blocked in PBS containing 3%
BSA and 0.1% Triton X-100 for 30 minutes at RT before
incubation with monoclonal anti-bIII-tubulin antibodies (1:200
dilution, Sigma-Aldrich, Poole, United Kingdom) for 1 hour at
RT. Cells then were washed in PBS and incubated with Alexa
Fluor 488 anti-mouse IgG (1:400 dilution, Invitrogen) for 1
hour at RT. After final washes in PBS, cells were coverslip-
mounted in Vectamount containing 40,6-diamidino-2-phenyl-
endole (DAPI; Vector Laboratories, Peterborough, United
Kingdom) and viewed under a Zeiss Axioplan 2 fluorescent
microscope equipped with an Axiocam HRc and Axiovision
software (all from Zeiss, Hertfordshire, United Kingdom).
Negative controls had primary antibody omitted and were used
to set the background threshold levels for nonspecific staining
before image capture.
RGC Neurite Outgrowth and Survival. The mean
number of surviving bIII-tubulinþ RGC, those with neurites
and the mean neurite lengths, were quantified at day 4 after
plating and treatment as described by us previously.39 Briefly,
the identity of chamber slides was masked by a second
investigator and wells split into nine quadrants. Images were
captured by the masked investigator from each quadrant using
a Zeiss Axioplan 2 fluorescent microscope equipped with an
Axiocam HRc and Axiovision Software (all from Zeiss). The
number of bIII-tubulinþ RGC and neurite lengths were
quantified using Axiovision software (Version 4.8; Zeiss) and
ImagePro (Version 6.3; Media Cybernetics, Bethesda, MD,
USA).
RGC survival was determined by counting the number of
bIII-tubulinþ RGC in each quadrant and multiplying by the
surface area of each well (n ¼ 3 wells/condition; three
independent repeats; total n ¼ 9 well/condition). The
proportion of RGC survival at 4 days after plating and
appropriate treatments was determined by counting the
number of bIII-tubulinþ RGC immediately after plating, as
decribed above. All data were analyzed by the investigator
masked to the treatment conditions.
LCM of RGC With and Without Neurites. Retinal cells
were stained with fluorescent lipophilic dye FMI-43 [N-(3-
triethylammoniumpropyl)-4-4-(4-(dibutylamino)styryl)pyridi-
nium dibromide] (Invitrogen) for 20 minutes,40 fixed with 4%
paraformaldehyde and 4% sucrose in PBS for 10 minutes,
dehydrated through a graded series of ethanols and air-dried.
An LCM microscope (Arcturus Pixcell II; Applied Biosystems,
Rugby, United Kingdom) was used to isolate 1000 FMI-43þRGC
with and without neurites in each experiment and the RNA
extracted, amplified, and quantitative (q)RT-PCR performed as
described below. Experiments were repeated on three
independent occasions.
In Vivo Experiments
Experimental Design. To assess the effects of intravitreal
PN grafts on BMP4/Smad1 activation, three Fischer rats/group
(repeated on three independent occasions; total n ¼ 18 eyes/
optic nerves/group) were used (Fig. 1B) to avoid graft
rejection. Animals were assigned randomly to treatment groups
and masked to the investigator. Groups included: (1) intact, (2)
ONC, and (3) ONCþPN.
To assess activation of Smad1 after intravitreal BMP4
injection, three rats/group (three independent repeats; total
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¼ 18 eyes/group) were used and included: (1) intact controls,
(2) ONCþPBS (vehicle), and (3), ONCþBMP4 (5 lg BMP4
dissolved in a final volume of 5 lL PBS; dosage preoptimized to
cause maximal RGC survival in vivo [not shown]). Animals
received intravitreal injections of PBS or BMP4 immediately
after injury and were killed at 7 days and prepared for
immunohistochemistry for phosphorylated (p) Smad1
(pSmad1).
The effects of BMP4 on RGC survival and axon regeneration
were studied in three rats/group (repeated on three indepen-
dent occasions, total n ¼ 18 eyes/ON/group) at 24 days after
ONC and treatment; the groups included: (1) intact controls,
(2) ONCþPBS (vehicle; to control for the effects of multiple
intravitreal injections), and (3) ONCþBMP4 (5 lg BMP4; Fig.
1C). To assess if RGC axon regeneration promoted by BMP4
was rapamycin-sensitive (i.e., mTORC1-dependent), n¼ 3 rats/
group (n ¼ 18 eyes/ON/treatment); the groups included: (1)
BMP4þvehicle and (2) BMP4þrapamycin. Rapamycin was
prepared and administered as described previously.10 Briefly,
rapamycin stock solutions were dissolved at 20 mg/mL in
ethanol and, before each administration, diluted in 5% Tween
80, 5% polyethylene glycol 400 in PBS. Either rapamycin or
vehicle was injected intraperitoneally immediately after ONC
and every 2 days thereafter at a final concentration of 6 mg/mL.
ONC Group
All animal procedures were approved by the University of
Birmingham local animal welfare and ethical review board and
licensed by the UK Home Office. Surgery was done in strict
accordance with the UK Animals Scientific Procedures Act,
1986 and the Revised European Directive 1010/63/EU
according to the guidelines and recommendations for the use
of animals by the Federation of the European Laboratory
Animal Science Associations. Experiments also conformed to
the ARVO Statement for Use of Animals in Ophthalmic and
Vision Research except that bilateral ONC was enforced by the
UK Home Office as a means of reducing animal numbers, in
keeping with the 3R’s principle. Adult, female 6- to 8-week-old
Sprague-Dawley or Fischer rats (according to experiment)
were anesthetized using isofluorane inhalation and bilateral
ONC performed 2 mm from the lamina cribrosa as described
by us previously.32 Animals were monitored throughout the
study using an ophthalmoscope to detect damage to the lens or
cataracts. No animal showed lens damage or suffered cataracts
confirming that the lens had not been injured during surgery
and, thus, all eyes were included for analysis. Animals were
killed 5 days after ONC and retinal cells cultured as described
below. For implantation of a PN graft, a 0.5 cm length of donor
sciatic nerve was excised, teased between watchmaker’s
forceps and grafted intravitreally and held in place using
Spongostan. Two days before killing animals at 24 days,
lysinated rhodamine dextran (LRD) was injected into the distal
portion of the optic nerve 5 mm beyond the ONC site. LRDþ
RGC was used to identify cells that grew axons 5 mm beyond
the lesion site in vivo.
Immunohistochemistry for RBPMS and bIII-tubulin in radial
sections of the eye were used to assess RGC survival.
Phosphorylated (p) Smad1 immunoreactivity was used to
detect Smad1 pathway activation. GAP43 immunoreactivity in
longitudinal sections of the optic nerve was used to assess RGC
axon regeneration.38 All data were captured and analyzed with
the investigator masked to the treatment conditions.
RNA Extraction and Amplification. RNA was extracted
from LCM captured RGC using RNAqueous Microkit (Ambion,
Inc., Foster City, CA, USA; typically a yield of 1 ng from 1000
RGC) following the protocol of Zivraj et al.40 The extracted
RNA was linearly amplified using the two-cycle TargetAmp kit
(Epicentre, Madison, WI, USA) with a final yield of 36 lg
amplified (a)RNA. RNA quality was assessed on an Agilent 2100
Bioanalyzer (Agilent Technologies) before qRT-PCR.
qRT-PCR Analysis. Selected mRNA (Table 1) were
validated by qRT-PCR by preparing complementary DNA from
extracted RNA and qRT-PCR was performed using a Light-
Cycler real time qRT-PCR machine (Roche, Burgess Hill, United
Kingdom) according to previously published methods.41 Fold-
changes in mRNA were calculated using the DDCt method.41
Immunohistochemistry. Eyes from perfusion-fixed ani-
mals were removed, cryoprotected through a graded series of
sucrose solution and blocked in OCT (TAAB Laboratories,
Berks, United Kingdom). Radial cryosections of eyes were
adhered onto charged glass slides and immunohistochemistry
(IHC) performed on sections thawed and washed in PBS.
Nonspecific binding was blocked before incubation with the
relevant primary antibody (Table 2) overnight at 48C. Negative
controls, including ommision of primary antibodies were
included in each run to set the background threshold before
image capture. Sections then were washed in PBS, incubated
with relevant secondary antibodies conjugated to either
Alexa488 or Texas Red for 1 hour at RT, washed in further
changes of PBS and mounted using Vectashield containing
DAPI (Vector Laboratories).34,42 Sections were examined using
a Zeiss epi-fluorescent microscope attached to an Axiocam
HRc and run using Axiovision software (all from Zeiss), with an
experimenter masked to the treatment conditions.
Quantification of RGC Survival. RGC survival was
quantified as described previously.43 Briefly, sections contining
the optic disc were selected from each eye and the number of
RBPMSþ RGC were quantified along 250 lm lengths either side
of the optic nerve head in four consecutive sections/retina.
Quantification of Mu¨ller Cell Activation. Retinal Mu¨ller
cell activation was quantified in glial fibrillary acidic protein
TABLE 1. List of Primers Used for the BMP4/Smad1 and PTEN/mTOR
Pathways
Gene
Primer Sequence
Cat No/Reaction ID Source
gap43 4331182, Rn00567901_m1 ThermoFisher
sprr1a 4331182, Rn02061965_s1 ThermoFisher
cebp-epsilon 4331182, Rn00567306_g1 ThermoFisher
atf3 4331182, Rn00563784_m1 ThermoFisher
galanin 4331182, Rn00583681_m1 ThermoFisher
socs-3 4331182, Rn00585674_s1 ThermoFisher
bmp-4 4331182, Rn0043287_m1 ThermoFisher
smad1 4331182, Rn00565555_m1 ThermoFisher
smad5 4331182, Rn00572484_m1 ThermoFisher
smad8 4331182, Rn01494797_m1 ThermoFisher
smurf1 4331182, Rn01412801_m1 ThermoFisher
erk1/2 4331182, Rn00820922_g1 ThermoFisher
smif 4351372, Rn01214158_m1 ThermoFisher
msg1 4351372, Rn06396495_g1 ThermoFisher
tgif 4331182, Rn01418715_m1 ThermoFisher
sip1 4331182, Rn00584534_m1 ThermoFisher
pten 4331182, Rn00477208_m1 ThermoFisher
rheb 4331182, Rn00566263_m1 ThermoFisher
mtor 4331182, Rn00693900_m1 ThermoFisher
s6k1 4331182, Rn01760380_m1 ThermoFisher
4ebp1 4331182, Rn00587524_m1 ThermoFisher
tsc1 4331182, Rn00573107_m1 ThermoFisher
tsc2 4331182, Rn00562086_m1 ThermoFisher
redd1 4331182, Rn01433735_g1 ThermoFisher
akt 4331182, Rn00583646_m1 ThermoFisher
gapdh 4331182, Rn01775763_g1 ThermoFisher
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(GFAP)–stained radial eye sections by counting the number of
GFAPþMu¨ller cell processes along a 250 lm long sampling line
set orthogonal to the radial plane through the middle of the
inner plexiform layer (IPL), with the experimenter masked to
the treatment conditions, as described by us previously.44
Statistical Analysis
Significant differences were calculated between sample means
by 1-way ANOVA with post hoc test using Tukey’s method in
SPSS Version 24 (IMB Corporation, Armonk, NY, USA).
To determine statistical differences between treated and
vehicle groups for GAP43þ RGC axon regeneration, a
generalized linear mixed model was used in R statistics
package (available in the public domain at www.r-project.
org). Binomial GLMMs were fitted in R using package lme4
with the glmer function. P values then were calculated using
parametric bootstrap.45
RESULTS
LCM of RGC With Neurites Correlated With
Increased Expression of Regeneration Related
Genes
LCM was efficient at targeted removal of cell bodies from RGC
with and without neurites in na¨ıve retinal cultures treated with
combined NTF (Fig. 2A). When RGC with and without neurites
were compared, regeneration-related gap43, Sprr1a, c/ebp-
epsilon, atf3, and galanin mRNA were 8-, 34-, 30-, 5.4-, and 10-
fold upregulated in RGC with neurites, respectively, while
SOCS3 mRNA levels remained unchanged (Fig. 2C). Analysis of
components of the BMP4/Smad1 pathway in RGC treated with
combined NTF in culture also showed that bmp4, smad1,
smad4, smad5, smad8, smif, and msg1 mRNA were upregu-
lated 3.2-, 4.5-, 5.5-, 2-, 3-, 3-, and 2-fold, respectively (P < 0.05–
P < 0.0001), in RGC with neurites compared to RGC without
neurites (Fig. 2D). These results suggested that RGC that grow
neurites in culture have a regenerative phenotype and
upregulate genes in the BMP4/Smad1 pathway.
LCM of RGC With Neurites 21 days After ONCþPN
Correlates With Changes in Regeneration-Related
mRNA
After ONCþPN and subsequent culture of RGC, LRD injection
into the distal segment of the optic nerve, beyond the ONC
site, identified RGC that had regenerated axons through and
beyond (Fig. 2E), whereas FMI-43 labeled all cells in culture,
including RGC without neurites which were LRD (Fig. 2F).
There was a 15-, 40-, 35-, 12.4-, and 12-fold increase in
regeneration-related gap43, Sprr1a, c/ebp-epsilon, atf3, and
galanin mRNA, respectively, with no change in SOCS3 mRNA
levels in RGC with and without neurites (Fig. 2G). These
results are comparable with those seen in RGC treated with
combined NTF (compare Figs. 2C and 2G), suggesting that a
consistent profile of regeneration-related genes was switched
on in RGC with neurites compared to RGC without neurites.
The results also showed that some RGC survived for 21 days in
vivo after ONCþPN, but did not grow their neurites when
placed in culture.
Levels of mRNA for the BMP4/Smad1 pathway were
significantly higher in cultured RGC that had been harvested
21d after ONCþPN treatment when compared to RGC in
cultures prepared from na¨ıve eyes treated with combined NTF
(Fig. 2H). For example, bmp4, smad1, smad4, smad5, smad8,
smif, and msg1 mRNA levels were 15-, 24.5-, 25.5-, 9-, 10-, 12-,
and 13-fold upregulated, respectively (P < 0.0001), in RGC
with neurites compared to RGC without neurites (Fig. 2H).
These results suggested that intact and ONCþPN-treated
cultured RGC that grow neurites activate the BMP4/Smad1
signaling pathway.
ONCþPN Activated the BMP4/Smad1 Signaling
Pathway in RGC In Vivo
Immunohistochemistry in intact control and ONC eye sections
contained few bIII-tubulinþ RGC that also were BMP4þ (Fig.
2I). However, after ONCþPN treatment, many bIII-tubulinþ
RGC were BMP4þ (Fig. 2I). Few bIII-tubulinþ RGC were
phosphorylated (p) Smad1þ in intact controls (Fig. 2J), but
after ONC, some bIII-tubulinþ RGC were pSmad1þ, while after
ONCþPN treatment, most bIII-tubulinþ RGC were pSmad1þ
(Fig. 2J), indicating that the BMP4/Smad1 pathway was highly
active in RGC regenerating their axons in vivo.
BMP4 Peptide Promoted RGC Survival and Neurite
Outgrowth on a CME Substrate
Increasing concentrations of BMP4 peptide from 0 to 300 ng/
mL increased the % bIII-tubulinþ RGC in retinal cultures to a
maximum of 68% 6 7% (P < 0.0001) at 200 ng/mL,
significantly greater than that observed in cultures without
added BMP4 (32 6 9%; Figs. 3A, 3D). The mean percentage of
RGC with neurites and mean neurite length also increased in a
dose-dependent manner to a maximum of 26 6 3% (P <
0.0001) with 200 ng/mL and 238 6 27 lm (P < 0.0001),
respectively (Figs. 3B–D), despite the presence of inhibitory
CME. These results suggested that BMP4 is a potent RGC
survival and neuritogenic factor.
Knockdown of BMP4 Receptors or Downstream
Smad1 Abrogates BMP4-Induced RGC Survival and
Neurite Outgrowth
Approximately 70% knockdown of appropriate mRNA was
achieved in RGC cultures treated with siBMPR1a (Fig. 4A),
siBMPR1b (Fig. 4B), siSmad1 (Fig. 4C), and siACVR1 (Fig. 4D).
Knockdown of BMPR1a, BMPR1b, ACVR1, or Smad1 in the
presence of BMP4 peptide stimultaion not only suppressed
RGC survival to levels achieved with NBA alone (Fig. 4E), but
also significantly inhibited RGC neurite outgrowth (Fig. 4F) in
terms of percentage RGC with neurites (Fig. 4G) and the mean
neurite length (Fig. 4H). These results suggested that inhibition
of BMPR or Smad1 by siRNA block the survival and neurite
outgrowth properties of BMP4 peptide.
TABLE 2. List of Primary and Secondary Antibodies Used in This Study
Antibody Source Dilution
Primary antibodies
Mouse anti-bIII-tubulin Sigma-Aldrich 1:400
Rabbit anti-pSmad1 Cell Signaling Technology 1:200
Rabbit anti-BMP4 Abcam 1:400
Mouse anti-GAP-43 Invitrogen 1:200
Rabbit anti-GFAP Sigma-Aldrich 1:400
Rabbit anti-RBPMS Abcam 1:400
Secondary antibodies
Alexa-488 anti-rabbit Invitrogen 1:400
Alexa-488 anti-mouse Invitrogen 1:400
Alexa-594 anti-mouse Invitrogen 1:400
Alexa-594 anti-rabbit Invitrogen 1:400
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BMP4 Enhanced RGC Survival, Axon Regeneration
and Mu¨ller Glial Activation In Vivo
Few, if any cells in the ganglion cell layer (GCL) were pSmad1þ
in either intact retina or in retinae at 7 days after ONCþvehicle
treatment (Figs. 5A, 5B), a time-point where there is some 20%
to 40% RGC loss.46 However, intravitreal injection of BMP4
after ONC led to a significant increase in the number of
ganglion cells with pSmad1þ immunoreactivity (Figs. 5A, 5B).
Immunolabeling for pSmad1 (green) colocalized to bIII-
tubulinþ (red) cells in the GCL (Fig. 5C; arrowheads),
suggesting activation of the BMP4/Smad1 signaling pathway
in RGC. The number of RBPMSþ RGC/mm at 24 days after ONC
and treatment reduced from 61 6 3 in intact controls to 5 6 1
after ONC and vehicle treatment (Figs. 5D, 5E). BMP4
treatment promoted the survival of 16 6 2 RGC/mm, equating
to a significant increase in RGC of 31% compared to vehicle
treated groups (P < 0.001). BMP4 also promoted a significant
FIGURE 2. Regenerating RGC upregulate BMP4/Smad1 signaling. LCM of (A) before and (B) after collection of RGC somata from FMI-43þ RGC with
(red arrows) and without (white arrowheads) neurites, stimulated by combined NTF (FGF2/BDNF/NGF). (C) Changes in regeneration-related
mRNA in RGC (normalized to freshly isolated intact controls) with and without neurites and (D) in BMP4/Smad1 pathway. LCM of ONCþPN-
stimulated regenerating (E) LRDþ/(F) FMI-43þ (red arrows) and nonregenerating (LRD/FMI-43þ; white arrowheads) RGC showed similar changes
in (G) regeneration-related mRNA in RGC with/without neurites compared to na¨ıve retinal cultures. (H) Changes in mRNA levels of BMP4/Smad1
pathway molecules in regenerating and nonregenerating RGC prepared at 21 days after ONCþPN implantation mirrored that in intact control
cultures except that levels of all mRNA were significantly higher. Immunohistochemistry to demonstrate (I) absence of BMP4 (red) in bIII-tubulinþ
RGC (green) in intact or after ONC, but most RGC in the GCL were positive for BMP4 after ONCþPN treatment. (J) No pSmad1þ (red)
immunoreactivity was localized in bIII-tubulinþ RGC (green) in intact eyes. However, some pSmad1þ RGC were present after ONC, but nearly all
RGC in the GCL were positive for pSmad1 after ONCþPN treatment. (A, B, E, F) Scale bars: 50 lm, (I, J) Scale bars: 25 lm. **P < 0.01; ***P <
0.0001.
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increase in GAP43þ axons present at 100 (P < 0.05), 200 (P <
0.003), and 400 (P < 0.05) lm beyond the lesion site
compared to vehicle-treated groups in vivo (Figs. 5F, 5G).
These data showed that BMP4 significantly enhanced RGC
survival and axon regeneration in vivo.
The number of GFAPþ fibers crossing the IPL increased
significantly to 16 6 6 in vehicle-treated compared to intact
eyes (Figs. 5H, 5I; P < 0.009). However, BMP4 treatment
further increased the number of GFAPþ fibers crossing the IPL
to 35 6 2 compared to vehicle treated eyes (Figs. 5H, 5I; P <
0.004) amounting to a 46% increase compared to vehicle-
treated eyes. These results demonstrated that BMP4 treatment
also activates retinal glia.
BMP4-Stimulated RGC Neurite Outgrowth and
Axon Regeneration was Rapamycin-Insensitive
The addition of neither vehicle nor rapamycin (Fig. 6A) to
optimal BMP4 peptide-treated retinal cultures (200 ng/mL) did
not affect the levels of RGC survival (Fig. 6B), the percentage
RGC with neurites (Fig. 6C), and the mean neurite length (Fig.
6D) in the presence of CME, suggesting that PI3K/mTOR/pS6
signaling was not involved in BMP4-stimulated RGC survival
and neurite outgrowth (compare Figs. 6A–D with Figs. 3A–D).
In addition, neither vehicle nor rapamycin affected BMP4-
stimulated RGC axon regeneration in vivo (Figs. 5E, 5F). These
results suggested that BMP4-stimulated RGC neurite outgrowth
and axon regeneration are insensitive to rapamycin and, hence,
mTORC1-independent.
DISCUSSION
The results of this study demonstrated that the BMP4/Smad1
pathway is highly active and correlates positively with RGC
survival and neurite outgrowth/axon regeneration. BMP4
peptide addition in vitro and intravitreal delivery in vivo
promoted significant disinhibited RGC neurite outgrowth and
RGC survival and axon regeneration after ONC. In addition,
delivery of BMP4 peptide in vivo promoted glial activation.
Moreover, BMP4-stimulated RGC survival and neurite out-
growth and axon regeneration were insensitive to rapamycin
and, hence, were mTORC1-independent. These results implied
that activation of the BMP4/Smad1 pathway may be an
additional target for therapeutic manipulation in the search
for pan RGC axon regeneration.
Several studies have demonstrated that activation of the
PTEN/mTOR pathway, usually by genetic deletion of PTEN or
shRNA against PTEN10,22,47,48 and codeletion of PTEN/
SOCS3,5 promotes the survival and regeneration of approx-
imately 10% of all RGC in the murine retina.22 It seems
apparent that no matter what the regenerative strategy in the
optic nerve, only the ipRGC survive and regenerate their
axons (i.e., <10% RGC).49,50 This is despite the multiplicity
of neuroprotective/axogenic factors that includes mTOR
activation (either deletion of PTEN or tuberous sclerosis
complex 1 (TSC-1),10,11 trophic factors derived from
Schwann cells,39,51 macrophages,12,13 retinal glia,52,53 onco-
modulin,12–14 and ciliary neurotrophic factor/leukemia in-
hibitory factor.17,54–56
In this study, we showed that the BMP4/Smad1 pathway
was highly upregulated in RGC with neurites and also during
RGC axon regeneration in vivo, suggesting that this pathway is
an additional determinant of RGC neurite outgrowth/axon
regeneration. BMPs constitute a large family of proteins and
BMP signaling leads to phosphorylation of Smad1/5/8, which
then forms a complex with Smad4, translocates to the nucleus,
and regulates target gene expression.57,58 BMP has important
functions during development of the nervous system, but
BMP4 and BMP7 increase rapidly after spinal cord injury (SCI)
in the rat, with phosphorylation of Smad1/5/8 at the lesion
site.58–60 Moreover, overexpression of BMP4 in adult DRGN in
vitro and in vivo activated Smad1 and enhanced the axon
growth potential of DRGN in culture and after SCI in a mouse
model.30
BMPs have essential roles in retinal development23–25,61
and BMP-Smad1/5/8 is neuroprotective for RGC since
inhibiting BMP signaling reduces NMDA-induced RGC cyto-
toxicity.28 In addition, treatment with exogenous BMP4
promoted RGC survival after NMDA-induced damage.28 We
also showed that exogenous BMP4 not only promoted
significant RGC survival, but also promoted significant RGC
neurite outgrowth. RGC growing neurites correlated with
FIGURE 3. BMP4 peptide promotes RGC survival and disinhibited neurite outgrowth, effects that were insensitive to rapamycin. (A) Dose-
dependent increase in the percentage of surviving RGC, (B) percentage of RGC with neurites, and (C) the mean neurite length. (D) Examples of
RGC neurite outgrowth in treated cultures. ***P < 0.0001. (D) Scale bars: 100 lm.
BMP4/Smad1 Promotes RGC Survival and Axon Regeneration IOVS j April 2019 j Vol. 60 j No. 5 j 1754
Downloaded from iovs.arvojournals.org on 04/26/2019
significant activation of components in the BMP4/Smad1
pathway. In regenerating ONCþPN-treated eyes, we observed
activation of BMP4 and pSmad1 in almost all RGC in the
ganglion cell layer suggesting that BMP4/Smad1 signaling
correlates with a regenerative RGC phenotype. Furthermore,
BMP4 treatment in vivo promoted RGC survival, axon
regeneration, and retinal glial activation. Moreover, BMP4-
stimulated RGC neurite outgrowth/axon regeneration was
insensitive to rapamycin, suggesting that the BMP4/Smad1
pathway is mTORC1-independent. Together these results
suggested that BMP4/Smad1 is an additional signaling
pathway, important in regulating non-ipRGC survival and
axon regeneration. Our results agree with the observations
made in adult DRGN in the spinal cord and suggested that
reactivation of the BMP4/Smad1 pathway in adult CNS
neurons can restore their axon growth potential.
It is clear that activation of the BMP4/Smad1 pathway
stimulated RGC survival and axon regeneration (initiation and
elongation). However, the pro-survival effect of BMP4 was
small in scale and the morphology of surviving RBPMSþ RGC
in retinal cross-sections appear smaller and rounded com-
pared to untreated control retinas. Therefore, it is possible
that BMP4 delays the death of RGC and future experiments
will need to address this question before BMP4 can be used
therapeutically as a neuroprotective agent. Nonetheless, the
regenerative response to BMP4 was rapamycin-insensitive
and, hence, mTOR-independent, suggesting that the regener-
ation observed was probably in non-ipRGC. Although we did
not determine the subtype of RGC responding to BMP4/
FIGURE 4. Knockdown of BMPR and Smad1 attenuates BMP4-stumulated RGC survival and neurite outgrowth. Confirmation of approximately 70%
knockdown in (A) BMPR1a, (B) BMPR1b, (C) ACVR1, and (D) Smad1 mRNA in retinal cells by appropriate siRNAs. (E) Knockdown of BMPR and
Smad1 significantly reduced RGC survival. (F) Representative images from siControl and siBMPR1a and siSmad1-treated wells. Knockdown of BMPR
and Smad1 reduces (G) % RGC with neurites and (H) the mean neurite length. **P < 0.01; ***P < 0.0001, ANOVA. (F) Scale bars: 100 lm.
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Smad1 activation, future experiments could address whether
these constitute W3-RGC, M2-RGC, or ooDSGCs.22 It remains
to be investigated if any of the other 30 subtypes of RGC are
affected by BMP4 activation and, hence, the BMP4/Smad1
pathway presents itself as a valuable tool in determining the
differential survival and regenerative responses of different
RGC subtypes in the retina. Approximately 30% RGC survival
was achieved after BMP4 treatment in vitro and in vivo with
only 30% of those RGC growing neurites in culture and
probably a similar small number also regenerating their axons
in vivo. This suggested that RGC survival and axon
regeneration are likely to be signaled differently and, hence,
may require different combinations of neuroprotective/
trophic factors. Indeed, we have shown that RGC exclusively
activate cleaved caspase-2 after ONC injury and suppression
of caspase-2 with a siRNA (siCASP2) protects >95% RGC in
the rat retina.46,62,63 However, despite the survival of >95% of
RGC, siCASP2 treatment did not cause RGC axon regenera-
tion.62
In conclusion, our results showed that the BMP4/Smad1
pathway is activated in surviving and regenerating RGC.
Addition of exogenous BMP4 promoted non-ipRGC RGC
survival and disinhibited neurite outgrowth/axon regeneration
in vitro and in vivo, effects that were independent of mTOR
signaling. Our results suggested that the BMP4/Smad1 repre-
sents an additional therapeutic target to achieve pan RGC
survival and axon regeneration and, hence, restoration of lost
function.
FIGURE 5. BMP4 promotes RGC survival, axon regeneration and activates glia in vivo after ONC. (A) Representative images, (B) quantification, and (C)
double immunolabelling for pSmad1 and bIII-tubulin to show that exogenous BMP4 upregulates Smad1 signaling such that nearly all RGC in the GCL at
7 days after ONC were pSmad1þ. (D) RBPMSþ RGC immunohistochemistry and (E) quantification show reduced numbers of RBPMSþ RGC in vehicle-
treated ONC eyes compared to intact eyes; note that BMP4 treatment neuroprotected RGC. (F) GAP43 immunohistochemistry and (G) quantification
show significantly greater numbers of GAP43þ RGC axons regenerated 100, 200, and 400 lm beyond the ONC lesion site (*) after BMP4 treatment
compared to vehicle-treated groups. (H) GFAPþ reactive astrocyte somata and processes in the inner retinal layers and (I) quantification show
significantly increased numbers of reactive astrocyte processes traverse the inner plexiform layer (IPL) after treatment of ONC eyes with BMP4
compared to vehicle treatment. (A, C, E, G) Scale bars: 100 lm. **P < 0.001; ***P < 0.0001, ANOVA; #P < 0.05 and ##P < 0.003, GLMM.
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